BLUE LIGHT THERAPY FOR SLEEP IMPAIRMENTIN PARKINSON’S DISEASE
- Conditions
- Parkinson's Disease, sleep, light therapyZiekte van Parkinson, slaap, lichttherapie
- Registration Number
- NL-OMON20179
- Lead Sponsor
- Radboud University Medical Centre Nijmegen
- Brief Summary
1. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 1990;5(4):280-285.<br> 2. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clinical neuropharmacology. 1988;11(6):512-519.<br> 3. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Archives of neurology. 1997;54(5):625-630.<br> 4. Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. Experimental neurology. 2013;243:45-56.<br> 5. Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep medicine reviews. 2011;15(1):41-50.<br> 6. Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. Frontiers in neurology. 2017;8:42. 7. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology. 2002;58(7):1019-1024.<br> 8. Videnovic A, Willis GL. Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease? Movement disorders : official journal of the Movement Disorder Society. 2016;31(3):260-269.<br> 9. Boutrel B, Koob GF. What keeps us awake: The neuropharmacology of stimulants and wakefulness promoting medications. Sleep. 2004;27(6):1181-1194.<br> 10. Moore-Ede MC, Czeisler CA, Richardson GS. Circadian timekeeping in health and disease. Part 2. Clinical implications of circadian rhythmicity. N Engl J Med. 1983;309(9):530-536.<br> 11. Shochat T, Martin J, Marler M, Ancoli-Israel S. Illumination levels in nursing home patients: effects on sleep and activity rhythms. Journal of sleep research. 2000;9(4):373-379.<br> 12. Czeisler CA, Allan JS, Strogatz SH, et al. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science (New York, NY). 1986;233(4764):667-671.<br> 13. Wever RA, Polasek J, Wildgruber CM. Bright light affects human circadian rhythms. Pflugers Archiv : European journal of physiology. 1983;396(1):85-87.<br> 14. Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. European journal of neurology. 2010;17(4):550-554.<br> 15. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA neurology. 2014;71(5):589-595.<br> 16. Mattam U, Jagota A. Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration. Biogerontology. 2015;16(1):109-123.<br> 17. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-662.<br> 18. Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. Reviews in the neurosciences. 2012;23(2):199-226.<br> 19. Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiology international. 2007;24(3):521-537.<br> 20. Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Movement disorders : official journal of the Movement Disorder Society. 2007;22(10):1495-1498.<br> 21. Rutten S, Vriend C, van den Heuvel OA, Smit JH, Berendse HW, van der Werf YD. Bright light therapy in Parkinson's disease: an overview of the background and evidence. Parkinsons Dis. 2012;2012:767105.<br> 22. Kogan AO, Guilford PM. Side effects of short-term 10,000-lux light therapy. Am J Psychiatry. 1998;155(2):293-294.<br> 23. Lockley SW, Brainard GC, Czeisler CA. High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. The Journal of clinical endocrinology and metabolism. 2003;88(9):4502-4505.<br> 24. Ruger M, St Hilaire MA, Brainard GC, et al. Human phase response curve to a single 6.5 h pulse of short-wavelength light. The Journal of physiology. 2013;591(1):353-363.<br> 25. Gooley JJ, Rajaratnam SM, Brainard GC, Kronauer RE, Czeisler CA, Lockley SW. Spectral responses of the human circadian system depend on the irradiance and duration of exposure to light. Science translational medicine. 2010;2(31):31ra33.<br> 26. Viola AU, James LM, Schlangen LJ, Dijk DJ. Blue-enriched white light in the workplace improves self-reported alertness, performance and sleep quality. Scandinavian journal of work, environment & health. 2008;34(4):297-306.<br> 27. Rahman SA, Flynn-Evans EE, Aeschbach D, Brainard GC, Czeisler CA, Lockley SW. Diurnal spectral sensitivity of the acute alerting effects of light. Sleep. 2014;37(2):271-281.<br> 28. Vandewalle G, Gais S, Schabus M, et al. Wavelength-dependent modulation of brain responses to a working memory task by daytime light exposure. Cerebral cortex (New York, NY : 1991). 2007;17(12):2788-2795.<br> 29. Vandewalle G, Schmidt C, Albouy G, et al. Brain responses to violet, blue, and green monochromatic light exposures in humans: prominent role of blue light and the brainstem. PloS one. 2007;2(11):e1247.<br> 30. Daneault V, Hebert M, Albouy G, et al. Aging reduces the stimulating effect of blue light on cognitive brain functions. Sleep. 2014;37(1):85-96.<br> 31. Daneault V, Dumont M, Masse E, Vandewalle G, Carrier J. Light-sensitive brain pathways and aging. Journal of physiological anthropology. 2016;35:9.<br> 32. Roecklein KA, Wong PM, Miller MA, Donofry SD, Kamarck ML, Brainard GC. Melanopsin, photosensitive ganglion cells, and seasonal affective disorder. Neuroscience and biobehavioral reviews. 2013;37(3):229-239.<br> 33. Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA neurology. 2017;74(4):411-418.<br> 34. Artemenko AR, Levin Ia I. [The phototherapy of parkinsonism patients]. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 1996;96(3):63-66.<br> 35. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research. 1989;28(2):193-213.<br> 36. Post B, Merkus MP, de Bie RM, de Haan RJ, Speelman JD. Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Movement disorders : official journal of the Movement Disorder Society. 2005;20(12):1577-1584.<br> 37. Kawai M, Goda R, Otsuka T, et al. Antidepressant-like effect of bright light is potentiated by L-serine administration in a mouse model of seasonal affective disorder. Brain research bulletin. 2015;118:25-33.<br>
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Male or female subjects diagnosed with idiopathic PD according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria with Hoehn & Yahr stage 2-4
- Ability to obtain written inform consent (IC) for participation in the study
- Atypical Parkinsonism (Subjects with Parkinsonian features caused by disorder such as multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies or multiple brain infarcts)
- Severity of Parkinson’s disease defined as stage 1 or 5 according to Hoehn & Yahr stages
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of this study will be the change in Pittsburgh Sleep Quality Index score (PSQI).<br>
- Secondary Outcome Measures
Name Time Method The following parameter will serve as secondary outcome measures:<br /><br>a.Motor Symptoms measurements: <br /><br>-The MDS-Unified Parkinson’s Disease Rating scale (MDS-UPDRS) parts I-IV<br /><br>b.Non- motor symptoms measurements: <br /><br>-Sleep impairment: Epworth Sleepiness Scale (ESS), Global Impression of Clinical Change (GICC), sleep diary<br /><br>-Cognition: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA)<br /><br>-Depression and Anxiety: Hamilton Depression Rating Scale (HADS)<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.